[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biofrontera Inc (BFRI)

Biofrontera Inc (BFRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,004
  • Shares Outstanding, K 12,803
  • Annual Sales, $ 41,710 K
  • Annual Income, $ -10,540 K
  • EBIT $ -11 M
  • EBITDA $ -10 M
  • 60-Month Beta 0.78
  • Price/Sales 0.37
  • Price/Cash Flow N/A
  • Price/Book 2.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.17
  • Number of Estimates 1
  • High Estimate $-0.17
  • Low Estimate $-0.17
  • Prior Year $-0.57
  • Growth Rate Est. (year over year) +70.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9950 +37.69%
on 07/28/26
1.3800 -0.72%
on 08/13/26
+0.2600 (+23.42%)
since 07/13/26
3-Month
0.7304 +87.57%
on 05/18/26
1.3800 -0.72%
on 08/13/26
+0.4102 (+42.74%)
since 05/13/26
52-Week
0.5547 +146.98%
on 12/31/25
1.3800 -0.72%
on 08/13/26
+0.4200 (+44.21%)
since 08/13/25

Most Recent Stories

More News
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of...

BFRI : 1.3750 (+10.00%)
BFRIW : 0.0249 (+6.87%)
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz ® (aminolevulinic acid...

BFRI : 1.3750 (+10.00%)
BFRIW : 0.0249 (+6.87%)
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization...

BFRI : 1.3750 (+10.00%)
BFRIW : 0.0249 (+6.87%)
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy...

BFRI : 1.3750 (+10.00%)
BFRIW : 0.0249 (+6.87%)
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis

The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a photo,...

BFRI : 1.3750 (+10.00%)
BFRIW : 0.0249 (+6.87%)
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026

WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the development and commercialization...

BFRI : 1.3750 (+10.00%)
BFRIW : 0.0249 (+6.87%)
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing...

BFRI : 1.3750 (+10.00%)
BFRIW : 0.0249 (+6.87%)
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the development and commercialization...

BFRI : 1.3750 (+10.00%)
BFRIW : 0.0249 (+6.87%)
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris 

• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further...

BFRI : 1.3750 (+10.00%)
BFRIW : 0.0249 (+6.87%)
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable

WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”),...

BFRI : 1.3750 (+10.00%)
BFRIW : 0.0249 (+6.87%)

Business Summary

Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses,...

See More

Key Turning Points

3rd Resistance Point 1.3333
2nd Resistance Point 1.2967
1st Resistance Point 1.2733
Last Price 1.3750
1st Support Level 1.2133
2nd Support Level 1.1767
3rd Support Level 1.1533

See More

52-Week High 1.3800
Last Price 1.3750
Fibonacci 61.8% 1.0647
Fibonacci 50% 0.9674
Fibonacci 38.2% 0.8700
52-Week Low 0.5547

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.